Delving into the Latest Updates on Lanzhou Institute of Biological Products Co. Ltd. with Synapse

Overview

Basic Info

Introduction

Lanzhou Institute of Biological Products Co. Ltd. is a biopharmaceutical company based in China and is under the control of the Chinese government. The company specializes in the production of biological products.

Tags

Infectious Diseases

Other Diseases

Respiratory Diseases

Prophylactic vaccine

Live attenuated vaccine

Combination vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	37
Nervous System Diseases	4
Endocrinology and Metabolic Disease	1
Hemic and Lymphatic Diseases	1
Immune System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Prophylactic vaccine	37
Live attenuated vaccine	7
Combination vaccine	6
Inactivated vaccine	5
Conjugated vaccine	4

Top 5 Target	Count

CD52(CAMPATH-1 antigen)	1
GLP-1R(Glucagon-like peptide 1 receptor)	1
SNAP25(Synaptosomal-associated protein 25)	1
HIV-1 nef(Protein Nef)	1

To evaluate the efficacy of different dosing regimens of Botulinum Toxin Type A for Injection (HengLi®) in the treatment of trigeminal neuralgia (TN), so as to determine the optimal dosing regimen of the best administration scheme of Botulinum Toxin Type A for Injection (HengLi®) in the treatment of TN.

Start Date25 Apr 2024

Sponsor / Collaborator

Lanzhou Institute of Biological Products Co. Ltd.

CTR20240959 / RecruitingPhase 2

一项评估注射用 A 型肉毒毒素（衡力®）治疗三叉神经痛有效性、安全性和免疫原性的随机、双盲、平行、安慰剂对照、多中心 II 期临床试验

[Translation] A randomized, double-blind, parallel, placebo-controlled, multicenter phase II clinical trial to evaluate the efficacy, safety, and immunogenicity of botulinum toxin type A (Hengli®) for the treatment of trigeminal neuralgia

主要目的：评估注射用A型肉毒毒素（衡力®）不同给药方案治疗三叉神经痛（TN）的有效性，确定注射用A型肉毒毒素（衡力®）治疗TN的最佳给药方案。次要目的：评估注射用A型肉毒毒素（衡力®）不同给药方案治疗TN的疗效维持时间。评估注射用A型肉毒毒素（衡力®）多次给药后的有效性。

[Translation]

Primary purpose: To evaluate the effectiveness of different dosing regimens of botulinum toxin type A (Hengli®) for the treatment of trigeminal neuralgia (TN) and to determine the optimal dosing regimen of botulinum toxin type A (Hengli®) for the treatment of TN. Secondary purpose: To evaluate the duration of efficacy of different dosing regimens of botulinum toxin type A (Hengli®) for the treatment of TN. To evaluate the effectiveness of botulinum toxin type A (Hengli®) after multiple administrations.

Start Date28 Mar 2024

Sponsor / Collaborator

Lanzhou Biotechnique Development Co. Ltd.

NCT05916326 / Not yet recruitingPhase 3

A Phase III Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula Polymorpha) in Healthy People Aged 6 Months to 13 Years

The purpose of this study is to evaluate the Efficacy, Safety and Immunogenicity of the Human Norovirus Bivalent (GⅠ.1/GⅡ.4)Vaccine，Recombinant (Hansenula polymorpha) in Healthy People Aged 6 Months to 13 Years After Vaccination

Start Date01 Jun 2023

Sponsor / Collaborator

Lanzhou Institute of Biological Products Co. Ltd.

100 Clinical Results associated with Lanzhou Institute of Biological Products Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Lanzhou Institute of Biological Products Co. Ltd.

Login to view more data

367

Literatures (Medical) associated with Lanzhou Institute of Biological Products Co. Ltd.

03 Oct 2024·Microbiology Spectrum

Evaluation of human antibodies from vaccinated volunteers for protection against Yersinia pestis infection

Article

Author: Jiao, Lei ; Zheng, Binyang ; Zhang, Li ; Wu, Hailian ; Pan, Hongxing ; Zhou, Jianfang ; Lu, Jing ; Wu, Haisheng ; Zhang, Qi

01 Jun 2024·Applied Biochemistry and Biotechnology

Identification and Characterization of Two Novel Extracellular β-Glucanases from Chaetomium globosum against Fusarium sporotrichioides

Article

Author: Zhang, Ziyu ; Li, Jialu ; Li, Jiamin ; Zhou, Xingyu ; Zhang, Jinhu ; Jiang, Cheng ; Miao, Guopeng ; Zhu, Shuyan

Chaetomium globosum can inhibit the growth of fusarium by means of their extracellular proteins. Two novel β-glucanases, designated Cgglu17A and Cgglu16B, were separated from the supernatant of C. globosum W7 and verified to have the ability to hydrolyze cell walls of Fusarium sporotrichioides MLS-19. Cgglu17A (397 amino acids) was classified as glycoside hydrolase family 17 while Cgglu16B belongs to the family16 (284 amino acids). Recombinant protein Cgglu17A was successfully expressed in Escherichia coli, and the enzymes were purified by affinity chromatography. Maximum activity of Cgglu17A appeared at the pH 5.5 and temperature 50 °C, but Cgglu16B shows the maximum activity at the pH 5.0 and temperature 50 °C. Most of heavy metal ions had inhibition effect on the two enzymes, but Cgglu17A and Cgglu16B were respectively activated by Ba²⁺ and Mn²⁺. Cgglu17A exhibited high substrate specificity, almost only catalyzing the cleavage of β-1,3-glycosidic bond, in various polysaccharose, to liberate glucose. However, Cgglu16B showed high catalytic activities to both β-1,3-glycosidic and β-1,3-1,4-glycosidic bonds. Cgglu17A was an exo-glucanase, but Cgglu16B was an endo-glucanase based on hydrolytic properties assay. Both of two enzymes showed potential antifungal activity, and the synergistic effect was observed in the germination experiment of pathogenic fungus. In conclusion, Cgglu17A (exo-1,3-β-glucanase) and Cgglu16B (endo-1,3(4)-β-glucanase) were confirmed to play a key role in the process of C. globosum controlling fusarium and have potential application value on industry and agriculture for the first time.

01 May 2024·Biomedicine & Pharmacotherapy

Botulinum toxin type A inhibits M1 macrophage polarization by deactivation of JAK2/STAT1 and IκB/NFκB pathway and contributes to scar alleviation in aseptic skin wound healing

Article

Author: Zou, Yan-Ping ; Xiang, Ruo-Lan ; Shan, Xiao-Feng ; Wang, Lin-Na ; Qiu, Jia-Xuan ; Cai, Zhi-Gang

The non-neuronal and non-muscular effects of botulinum toxin type A (BTXA) on scar reduction has been discovered. This study was designed to investigate the effects of BTXA on macrophages polarization during the early stage of skin repair. A skin defect model was established on the dorsal skin of SD rats. BTXA was intracutaneous injected into the edge of wound immediately as the model was established. Histological examinations were performed on scar samples. Raw 264.7 was selected as the cell model of recruited circulating macrophages, and was induced for M1 polarization by LPS. Identify the signaling pathways that primarily regulated M1 polarization and respond to BTXA treatment. Application of BTXA at early stage of injury significantly reduced the scar diameter without delaying wound closure. BTXA treatment improved fiber proliferation and arrangement, and inhibited angiogenesis in scar granular tissue. The number of M1 macrophages and the levels of pro-inflammation were decreased after treated with BTXA in scar tissues. LPS activated JAK2/STAT1 and IκB/NFκB pathways were downregulated by BTXA, as well as LPS induced M1 polarization. At early stage of skin wound healing, injection of BTXA effectively reduced the number of M1 macrophages and the levels of pro-inflammatory mediators which contributes to scar alleviation. BTXA resisted the M1 polarization of macrophages induced by LPS via deactivating the JAK2/STAT1 and IκB/NFκB pathways.

100 Deals associated with Lanzhou Institute of Biological Products Co. Ltd.

Login to view more data

100 Translational Medicine associated with Lanzhou Institute of Biological Products Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

Preclinical

IND Application

1

3

IND Approval

Phase 1 Clinical

2

Phase 3 Clinical

NDA/BLA

1

35

Approved

Other

4

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Japanese Encephalitis Vaccine,Live(Lanzhou Institute of Biological Products Co. Ltd.)	Encephalitis, Viral More	Approved
BCG Vaccine for Intradermal Injection(Lanzhou Institute of Biological Products Co. Ltd.)	Tuberculosis More	Approved
Rabies Vaccine(Hamester Kidney Cell) for Human Use(Lanzhou Institute of Biological Products Co. Ltd.)	Rabies More	Approved
Pertussis Vaccine(Lanzhou Institute of Biological Products Co. Ltd.)	Whooping Cough More	Approved
Diluent for Meningococcal Polysacharide Vaccine (Sterile Pyrogen-free PBS)(Lanzhou Institute of Biological Products Co. Ltd.)	Meningococcal Infections More	Approved